{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:05:50Z","timestamp":1793880350825,"version":"4.7.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate, in an exploratory setting, the safety of adjunctive Naoxintong Capsule (NXT) added to standard secondary prevention in patients with acute coronary syndrome (ACS), and to describe between-group differences in major adverse cardiovascular events (MACE), psychological state, angina-related quality of life, lipid profile, cardiac function, and traditional Chinese medicine (TCM) syndrome measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>In this open-label, multicenter, exploratory randomized controlled trial, 170 ACS patients were randomized 1:1 to standard secondary prevention alone (control, n = 85) or combined with NXT (n = 85) for 12\u00a0months. The primary outcome was 12-month MACE (cardiac death, nonfatal myocardial infarction, urgent revascularization, ischemic stroke), ascertained by treating clinicians without an independent blinded events committee. Secondary outcomes included SAS, SDS, SAQ, lipid profile, echocardiographic parameters, TCM syndrome score, and safety indices. The primary analysis was complete-case; multiplicity was not pre-specified, and all secondary P values are nominal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 170 randomized participants, 152 completed 12-month follow-up (NXT n = 78; control n = 74; attrition 10.6%, balanced between arms). MACE was recorded in 8\/78 (10.3%) in the NXT arm vs. 13\/74 (17.6%) in control (relative risk 0.58; 95% CI 0.26\u20131.33; P = 0.19; not statistically significant, 95% CI included the null). A worst-case sensitivity check assigning all NXT-arm losses as events and all control-arm losses as non-events yielded 17.6% vs. 15.3%, indicating that the direction of the point estimate was not robust to missing-outcome assumptions. Nominally larger reductions in the NXT arm were observed for SAS (\u22128.75 vs. \u22123.75) and SDS (\u221210.00 vs. \u22123.75); nominally larger changes were also observed across SAQ domains, lipid parameters (TC, TG, LDL-C), and echocardiographic indices (LVEF, LVEDD, LVESD), all reported as nominal descriptive findings. Safety laboratory parameters did not differ between groups, and no serious adverse events occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this open-label exploratory trial, adjunctive NXT was not associated with a statistically significant reduction in MACE, and the direction of the estimate was not robust to missing-data assumptions. Between-group differences in secondary outcomes are hypothesis-generating only, given the open-label design, unblinded event ascertainment, absence of multiplicity adjustment, and complete-case analysis of a rare-event endpoint. Adequately powered, placebo-controlled, double-blind trials with independent blinded event adjudication are needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>Registered on July 22, 2020, with the registration number ChiCTR2000034871 at the Chinese Clinical Trial Registry.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1848036","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:36:08Z","timestamp":1785821768000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Naoxintong capsule as adjunctive therapy in ACS: a hypothesis-generating open-label randomized trial"],"prefix":"10.3389","volume":"17","author":[{"given":"Liyuan","family":"Yu","sequence":"first","affiliation":[{"name":"The Second Clinical Medical School of Guangzhou University of Chinese Medicine","place":["Guangzhou, China"]},{"name":"Guangdong Provincial Hospital of Traditional Chinese Medicine","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihang","family":"Peng","sequence":"additional","affiliation":[{"name":"Affiliated TCM Hospital of Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Wu","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Guangdong Pharmaceutical University","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairong","family":"Cai","sequence":"additional","affiliation":[{"name":"Guangdong Provincial Hospital of Traditional Chinese Medicine","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zeng","sequence":"additional","affiliation":[{"name":"Guangdong Provincial Hospital of Traditional Chinese Medicine","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bojun","family":"Chen","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical School of Guangzhou University of Chinese Medicine","place":["Guangzhou, China"]},{"name":"Guangdong Provincial Hospital of Traditional Chinese Medicine","place":["Guangzhou, China"]},{"name":"State Key Laboratory of Traditional Chinese Medicine Syndrome, Guangdong Provincial Key Laboratory of Research on Emergency in Traditional Chinese Medicine, Clinical Research Team of Prevention and Treatment of Cardiac Emergencies with Traditional Chinese Medicine","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.jacc.2024.05.038","article-title":"Treating depression to improve survival in coronary heart disease: what have we learned?","volume":"84","author":"Carney","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.3390\/nu15102288","article-title":"Red yeast rice for the improvement of lipid profiles in mild-to-moderate hypercholesterolemia: a narrative review","volume":"15","author":"Cicero","year":"2023","journal-title":"Nutrients"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e018897","DOI":"10.1161\/JAHA.120.018897","article-title":"Lipid management in patients presenting with acute coronary syndromes: a review","volume":"9","author":"Claessen","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur. Heart J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jchromb.2017.11.017","article-title":"Simultaneous determination of phenolic acids and diterpenoids and their comparative pharmacokinetic study in normal and acute blood stasis rats by UFLC-MS\/MS after oral administration of guan-xin-shu-tong capsules","volume":"1072","author":"Gao","year":"2018","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.phrs.2019.01.024","article-title":"The cardioprotective properties and the involved mechanisms of NaoXinTong capsule","volume":"141","author":"Han","year":"2019","journal-title":"Pharmacol. Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.chmed.2023.12.007","article-title":"Qishen granule protects against myocardial ischemia by promoting angiogenesis through BMP2-Dll4-Notch1 pathway","volume":"17","author":"Hong","year":"2025","journal-title":"Chin. Herb. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13020-021-00532-0","article-title":"Myocardial protective effect and transcriptome profiling of naoxintong on cardiomyopathy in zebrafish","volume":"16","author":"Hu","year":"2021","journal-title":"Chin. Med."},{"key":"B9","first-page":"1445","article-title":"Efficacy of shuganjieyu capsule for treatment of neurologic disorders combined with depression: a meta-analysis","volume":"35","author":"Huang","year":"2022","journal-title":"Pak J. Pharm. Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"533","DOI":"10.7326\/ANNALS-24-03102","article-title":"De-escalating dual antiplatelet therapy to ticagrelor monotherapy in acute coronary syndrome: a systemic review and individual patient data meta-analysis of randomized clinical trials","volume":"178","author":"Lee","year":"2025","journal-title":"Ann. Intern Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12943-024-02213-6","article-title":"Tailoring traditional Chinese medicine in cancer therapy","volume":"24","author":"Li","year":"2025","journal-title":"Mol. Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"106598","DOI":"10.1016\/j.nbd.2024.106598","article-title":"Sotagliflozin attenuates cardiac dysfunction and depression-like behaviors in mice with myocardial infarction through the gut-heart-brain axis","volume":"199","author":"Liao","year":"2024","journal-title":"Neurobiol. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jep.2016.12.014","article-title":"A traditional Chinese formula composed of chuanxiong rhizoma and gastrodiae rhizoma (da chuanxiong formula) suppresses inflammatory response in LPS -induced RAW 264.7 cells through inhibition of NF-\u03baB pathway","volume":"196","author":"Liu","year":"2017","journal-title":"J. Ethnopharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1142\/s0192415x24500253","article-title":"Traditional Chinese medicine for cancer treatment","volume":"52","author":"Liu","year":"2024","journal-title":"Am. J. Chin. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"843409","DOI":"10.3389\/fphar.2022.843409","article-title":"Naoxintong capsule alternates gut microbiota and prevents hyperlipidemia in high-fat-diet fed rats","volume":"13","author":"Lu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"124197","DOI":"10.1016\/j.jchromb.2024.124197","article-title":"Integrated metabolomics and network pharmacology approach to exploring the anti-inflammatory mechanisms of chuanwang xiaoyan capsules","volume":"1242","author":"Meng","year":"2024","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.tins.2012.08.004","article-title":"Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors","volume":"35","author":"Neumann","year":"2012","journal-title":"Trends Neurosci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"107712","DOI":"10.1016\/j.phrs.2025.107712","article-title":"Mitochondrial quality control: a promising target of traditional Chinese medicine in the treatment of cardiovascular disease","volume":"215","author":"Pan","year":"2025","journal-title":"Pharmacol. Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/ptr.8371","article-title":"Red yeast rice or lovastatin? A comparative evaluation of safety and efficacy through a multifaceted approach","volume":"39","author":"Rigillo","year":"2025","journal-title":"Phytother. Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1093\/ehjqcco\/qcae112","article-title":"Intersectionality of inequalities in revascularisation and outcomes for acute coronary syndrome in England: nationwide linked cohort study","volume":"11","author":"Roman","year":"2025","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1398934","DOI":"10.3389\/fphar.2024.1398934","article-title":"Effects of the combination of red yeast rice-containing commercial Chinese polyherbal preparation with statins for dyslipidemia: a systematic review and meta-analysis","volume":"15","author":"Shi","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e013263","DOI":"10.1161\/CIRCINTERVENTIONS.123.013263","article-title":"Antiplatelet De-Escalation strategies in patients undergoing percutaneous coronary intervention","volume":"17","author":"Spirito","year":"2024","journal-title":"Circ. Cardiovasc Interv."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.jacc.2024.10.125","article-title":"Antithrombotic therapy to minimize total events after ACS or PCI in atrial fibrillation: insights from AUGUSTUS","volume":"85","author":"Tannu","year":"2025","journal-title":"J. Am. Coll. Cardiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2018.08.1038","article-title":"Fourth universal definition of myocardial infarction (2018)","volume":"72","author":"Thygesen","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"10343","DOI":"10.3390\/ijms251910343","article-title":"CDNF exerts anxiolytic, antidepressant-like, and procognitive effects and modulates serotonin turnover and neuroplasticity-related genes","volume":"25","author":"Tsybko","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"155662","DOI":"10.1016\/j.phymed.2024.155662","article-title":"Naoxintong capsule remodels gut microbiota and ameliorates early-stage atherosclerosis in apolipoprotein E-deficient mice","volume":"129","author":"Wan","year":"2024","journal-title":"Phytomedicine"},{"key":"B27","doi-asserted-by":"publisher","first-page":"698","DOI":"10.2174\/1566524019666190207143207","article-title":"Naoxintong retards atherosclerosis by inhibiting foam cell formation through activating Ppar\u03b1 pathway","volume":"18","author":"Wang","year":"2018","journal-title":"Curr. Mol. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"106458","DOI":"10.1016\/j.fitote.2025.106458","article-title":"The efficacy and mechanisms of maiguanfukang tablets, a patented herbal-based TCM formula, for the treatment of atherosclerosis: an in vivo experiment based on the network pharmacology","volume":"182","author":"Wang","year":"2025","journal-title":"Fitoterapia"},{"key":"B29","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jgr.2024.08.004","article-title":"Panax notoginseng saponins promotes angiogenesis after cerebral ischemia-reperfusion injury","volume":"48","author":"Xiao","year":"2024","journal-title":"J. Ginseng Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1274000","DOI":"10.3389\/fphar.2024.1274000","article-title":"Comprehensive effect of naoxintong capsule combined with Western medicine on coronary heart disease after percutaneous coronary intervention: a meta-analysis","volume":"15","author":"Yu","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"114310","DOI":"10.1016\/j.jep.2021.114310","article-title":"Chemical composition, quality control, pharmacokinetics, pharmacological properties and clinical applications of fufang danshen tablet: a systematic review","volume":"278","author":"Zeng","year":"2021","journal-title":"J. Ethnopharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"119240","DOI":"10.1016\/j.jep.2024.119240","article-title":"Naoxintong capsule attenuates heart damage after ischemic stroke via nuclear factor-\u03baB\/pyrin domain-containing protein 3\/Caspase-1 signaling","volume":"341","author":"Zhang","year":"2024","journal-title":"J. Ethnopharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"3712500","DOI":"10.1155\/2022\/3712500","article-title":"An energy metabolism study on the efficacy of naoxintong capsules against myocardial infarction in a rat model","volume":"2022","author":"Zhao","year":"2022","journal-title":"Oxid. Med. Cell Longev."},{"key":"B34","doi-asserted-by":"publisher","first-page":"8147","DOI":"10.2147\/jir.s490815","article-title":"Study on the anti-atherosclerotic mechanisms of xin-tong-tai granule through network pharmacology, molecular docking, and experimental validation","volume":"17","author":"Zhu","year":"2024","journal-title":"J. Inflamm. Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1848036\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:36:10Z","timestamp":1785821770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1848036\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":34,"alternative-id":["10.3389\/fphar.2026.1848036"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1848036","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"article-number":"1848036"}}